200 related articles for article (PubMed ID: 16985070)
1. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
Barbieri E; Mehta P; Chen Z; Zhang L; Slack A; Berg S; Shohet JM
Mol Cancer Ther; 2006 Sep; 5(9):2358-65. PubMed ID: 16985070
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
3. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
4. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
5. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
6. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
7. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
8. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
9. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.
Chen L; Zhao Y; Halliday GC; Berry P; Rousseau RF; Middleton SA; Nichols GL; Del Bello F; Piergentili A; Newell DR; Lunec J; Tweddle DA
Br J Cancer; 2014 Aug; 111(4):716-25. PubMed ID: 24921920
[TBL] [Abstract][Full Text] [Related]
10. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
13. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
[TBL] [Abstract][Full Text] [Related]
14. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
[TBL] [Abstract][Full Text] [Related]
15. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.
Van Maerken T; Rihani A; Dreidax D; De Clercq S; Yigit N; Marine JC; Westermann F; De Paepe A; Vandesompele J; Speleman F
Mol Cancer Ther; 2011 Jun; 10(6):983-93. PubMed ID: 21460101
[TBL] [Abstract][Full Text] [Related]
17. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
18. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
